Generic medications tend to be Sandoz is building its GLP-1 development platform, and this submission reflects true in-house innovation, said Claire DAbreu-Hayling, the president of Generics Development and the chief scientific officer at Sandoz, in a press statement
Lecanemab, approved by the Food and Drug Administration last year, and donanemab, out earlier this month, are both antibody treatments built around the idea that reducing the presence of key amyloid plaques in the brain will help slow dementia progression
Appetite suppression diminishes
Disclaimer: This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment
Cysteine-mediated redox signaling: Chemistry, biology, and tools for discovery